A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Janet K. Johnson, Tesfaye Liranso, Keith Saylor, Gabriela Tulloch, Toyin Adewole, Stefan Schwabe, Azmi Nasser, Robert L. Findling, Jeffrey H. Newcorn

Research output: Contribution to journalArticle

Abstract

Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. Results: Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo (p <.05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly (p <.05) versus placebo. The most frequent AEs (≥15%) were somnolence, headache, and decreased appetite. Conclusion: SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.

Original languageEnglish (US)
Pages (from-to)348-358
Number of pages11
JournalJournal of Attention Disorders
Volume24
Issue number2
DOIs
StatePublished - Jan 1 2020

Fingerprint

Viloxazine
Placebos
Safety
Appetite
Suicide
Headache
Electrocardiography

Keywords

  • ADHD
  • attention deficit/hyperactivity disorder
  • nonstimulant
  • viloxazine

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Clinical Psychology

Cite this

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. / Johnson, Janet K.; Liranso, Tesfaye; Saylor, Keith; Tulloch, Gabriela; Adewole, Toyin; Schwabe, Stefan; Nasser, Azmi; Findling, Robert L.; Newcorn, Jeffrey H.

In: Journal of Attention Disorders, Vol. 24, No. 2, 01.01.2020, p. 348-358.

Research output: Contribution to journalArticle

Johnson, Janet K. ; Liranso, Tesfaye ; Saylor, Keith ; Tulloch, Gabriela ; Adewole, Toyin ; Schwabe, Stefan ; Nasser, Azmi ; Findling, Robert L. ; Newcorn, Jeffrey H. / A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. In: Journal of Attention Disorders. 2020 ; Vol. 24, No. 2. pp. 348-358.
@article{3ad7429070ce4b9f86084e1c093d3744,
title = "A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD",
abstract = "Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. Results: Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo (p <.05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly (p <.05) versus placebo. The most frequent AEs (≥15{\%}) were somnolence, headache, and decreased appetite. Conclusion: SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.",
keywords = "ADHD, attention deficit/hyperactivity disorder, nonstimulant, viloxazine",
author = "Johnson, {Janet K.} and Tesfaye Liranso and Keith Saylor and Gabriela Tulloch and Toyin Adewole and Stefan Schwabe and Azmi Nasser and Findling, {Robert L.} and Newcorn, {Jeffrey H.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1177/1087054719836159",
language = "English (US)",
volume = "24",
pages = "348--358",
journal = "Journal of Attention Disorders",
issn = "1087-0547",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

AU - Johnson, Janet K.

AU - Liranso, Tesfaye

AU - Saylor, Keith

AU - Tulloch, Gabriela

AU - Adewole, Toyin

AU - Schwabe, Stefan

AU - Nasser, Azmi

AU - Findling, Robert L.

AU - Newcorn, Jeffrey H.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. Results: Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo (p <.05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly (p <.05) versus placebo. The most frequent AEs (≥15%) were somnolence, headache, and decreased appetite. Conclusion: SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.

AB - Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. Results: Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo (p <.05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly (p <.05) versus placebo. The most frequent AEs (≥15%) were somnolence, headache, and decreased appetite. Conclusion: SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.

KW - ADHD

KW - attention deficit/hyperactivity disorder

KW - nonstimulant

KW - viloxazine

UR - http://www.scopus.com/inward/record.url?scp=85077328547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077328547&partnerID=8YFLogxK

U2 - 10.1177/1087054719836159

DO - 10.1177/1087054719836159

M3 - Article

C2 - 30924702

AN - SCOPUS:85077328547

VL - 24

SP - 348

EP - 358

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

SN - 1087-0547

IS - 2

ER -